Abstract 119P
Background
Gastric cancer (GC) remains the fifth most common malignancy worldwide accounting for over 1 million new cases and an estimated 769,000 deaths by 2020. Nearly 40% of the global GC cases occur in China, and the 5-year overall survival rate is less than 50%. Lymph node metastases (LNM) is an independent risk factor for prognosis and determines which treatments can be used in GC. LNM plays a crucial gateway role in cancer spread, but the underlying roles of LNM remain controversial, and there is no worldwide consensus. Therefore, the aim of this study was to investigate the clinical perspective and significance of LNM in GC via a retrospective study.
Methods
This study was performed on 129 patients who had gastric cancer with lymphadenectomy for the radical cure, whose specimens were obtained during surgery. Dissected lymph nodes were collected in groups and histopathological studies were performed to detect the lymph node metastasis and metastatic lymph node ratio (MLR). We also analyzed the relationships between rates of lymph node metastasis and tumor diameters, tumor localization, infiltrating depth, histological category, Borrmann typing, and so on.
Results
Among 129 patients with gastric cancer, lymph node metastases were found in 80 patients (62.02%) with a total collection of 3295 lymph nodes and an average of 25.54 lymph nodes per patient. The number of lymph nodes with metastasis was 889. Lymph node metastasis was associated with tumor size, the depth of invasion, Borrmann type, location and histological type. There were correlations between the total number of lymph nodes from 129 gastric cancer patients, metastatic lymph node numbers and MLR. Analysis of the survival curve showed that the survival time and rate had a negative correlation with the TNM stage and MLR.
Conclusions
According to the clinical and pathological factors, the characteristics of lymph node metastasis by groups and stations in different areas, and properly choosing and extending the extent of lymph node resection, the objective of the radical cure for gastric cancer could be achieved individually when radical lymphadenectomy is performed.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Technology Innovation Guidance Special Program of Shaanxi Province (2022QFY01-08), Key Research and Development Program of Shaanxi Province (2021SF-288), Natural Science Basic Research Program of Shaanxi Province (2020JQ-950, 2022JM-570), Health Research Program of Shaanxi Province (2022D002).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
79P - Outcomes by baseline liver function in patients with unresectable hepatocellular carcinoma treated with tremelimumab and durvalumab in the phase III HIMALAYA study
Presenter: Arndt Vogel
Session: Poster viewing 02
82P - A randomized controlled, open-label, adaptive phase III clinical trial to evaluate safety and efficacy of EndoTAG-1 plus gemcitabine versus gemcitabine alone in patients with measurable locally advanced and/or metastatic adenocarcinoma of the pancreas after FOLFIRINOX
Presenter: Muh-Hwan Su
Session: Poster viewing 02
83P - Impact of viral aetiology in the phase III HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC)
Presenter: Stephen Chan
Session: Poster viewing 02
84P - Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: A large real life worldwide population
Presenter: Margherita Rimini
Session: Poster viewing 02
86P - Outcomes by primary tumour location in patients with advanced biliary tract cancer treated with durvalumab or placebo plus gemcitabine and cisplatin in the phase III TOPAZ-1 study
Presenter: Aiwu Ruth He
Session: Poster viewing 02
87P - Socio-demographic disparities in esophageal cancer: A SEER analysis
Presenter: Beas Siromoni
Session: Poster viewing 02